Evidence map›Paper›PMID 31309294›Full record

Observational studyRheumatology international2019

Depression/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study.

Sanja Milutinovic, Kristina Veljkovic, Maja Zlatanovic, Goran Radunovic, Nemanja Damjanov

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. MRI Findings in Axial Psoriatic Spondylarthritis.Diagnostics (Basel, Switzerland) · 2023
    Review
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sanja MilutinovicInstitute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
Kristina VeljkovicDepartment of Probability and Statistics, Faculty of Mathematics, University of Belgrade, Belgrade, Serbia. kristina@matf.bg.ac.rs.ORCID http://orcid.org/0000-0002-3110-8079
Maja ZlatanovicInstitute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
Goran RadunovicInstitute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
Nemanja DamjanovInstitute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess prevalence and change of depression/anxiety symptoms in spondyloarthritis patients and feasibility of depression/anxiety questionnaires. 43 Patients with axial spondyloarthritis (axSpA) and 27 patients with psoriatic arthritis (PsA) were consecutively recruited. There were 34 patients on biologics and 36 patients on nonbiologics. Patients were not previously treated for depression. The demographic variables, pain, patient global assessment, laboratory, clinical findings, diseases activity scores, Beck Depression Inventory (BDI) and Depression Anxiety and Stress Scale-short version (DASS-21) were collected. The study visits were at the beginning, after 1 month, after 3 and after 6 months. In axSpA and PsA patients on biologics, BDI and DASS-21 were significantly lower compared to nonbiologics group during time. The axSpA patients on biologics had significantly lower BDI and depression severity by BDI at each time point and lower DASS-21 after 1, 3 and 6 months. BDI in PsA patients who received biological therapy was significantly lower after 3 and 6 months. In biologics groups, BDI significantly decreased after 3 months in axSpA patients and after 1 month in PsA patients. In axSpA patients, there was a medium correlation between BDI and axial pain, patient global assessment and disease activity scores. The biological therapy significantly affected the depression/anxiety symptoms in axSpA and PsA during time. BDI moderately correlated with pain and disease activity in axSpA. BDI and DASS-21 are easy to use in daily practice.

Indexed as

AdultAffectAntirheumatic AgentsAnxietyArthritis, PsoriaticBiological ProductsDepressionFeasibility StudiesFemaleHumansMaleMental HealthMiddle AgedPilot ProjectsPrevalenceSerbiaAntirheumatic AgentsBiological ProductsBDIBiological therapyDASS-21Depression/anxiety symptomsSpondyloarthritis

Identifiers

PMID31309294
OpenAlexW2959685543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.